Voya Financial Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.81M | Sell |
33,702
-552
| -2% | -$29.9K | 0.18% | 53 |
|
|
2025
Q4 | $1.68M | Sell |
34,254
-520
| -1% | -$24.3K | 0.16% | 59 |
|
|
2025
Q3 | $1.43M | Buy |
34,774
+802
| +2% | +$31.3K | 0.14% | 75 |
|
|
2025
Q2 | $1.31M | Buy |
33,972
+5,093
| +18% | +$195K | 0.13% | 82 |
|
|
2025
Q1 | $1.12M | Buy |
28,879
+3,022
| +12% | +$111K | 0.12% | 86 |
|
|
2024
Q4 | $870K | Buy |
25,857
+5,518
| +27% | +$199K | 0.09% | 105 |
|
|
2024
Q3 | $828K | Buy |
20,339
+176
| +0.9% | +$7.2K | 0.09% | 106 |
|
|
2024
Q2 | $779K | Buy |
20,163
+1,178
| +6% | +$49.6K | 0.09% | 106 |
|
|
2024
Q1 | $816K | Buy |
18,985
+1,224
| +7% | +$50.5K | 0.09% | 103 |
|
|
2023
Q4 | $659K | Sell |
17,761
-289
| -2% | -$10.4K | 0.08% | 117 |
|
|
2023
Q3 | $656K | Buy |
+18,050
| New | +$641K | 0.08% | 109 |
|
|
2021
Q2 | – | Sell |
-8,272
| Closed | -$376K | – | 391 |
|
|
2021
Q1 | $376K | Sell |
8,272
-3,488
| -30% | -$158K | 0.01% | 487 |
|
|
2020
Q4 | $544K | Sell |
11,760
-10,106
| -46% | -$464K | 0.02% | 386 |
|
|
2020
Q3 | $1.02M | Sell |
21,866
-4,339
| -17% | -$217K | 0.05% | 250 |
|
|
2020
Q2 | $1.33M | Sell |
26,205
-4,704
| -15% | -$241K | 0.07% | 210 |
|
|
2020
Q1 | $1.45M | Sell |
30,909
-6,239
| -17% | -$333K | 0.08% | 172 |
|
|
2019
Q4 | $2.19M | Sell |
37,148
-209
| -0.6% | -$11.6K | 0.11% | 142 |
|
|
2019
Q3 | $1.98M | Sell |
37,357
-506
| -1% | -$26K | 0.11% | 146 |
|
|
2019
Q2 | $1.89M | Buy |
37,863
+1,814
| +5% | +$91K | 0.1% | 152 |
|
|
2019
Q1 | $1.89M | Buy |
36,049
+453
| +1% | +$22.6K | 0.11% | 151 |
|
|
2018
Q4 | $1.7M | Sell |
35,596
-1,678
| -5% | -$82.6K | 0.11% | 147 |
|
|
2018
Q3 | $1.89M | Buy |
37,274
+1,588
| +4% | +$80.7K | 0.11% | 156 |
|
|
2018
Q2 | $1.76M | Buy |
35,686
+6,645
| +23% | +$335K | 0.11% | 156 |
|
|
2018
Q1 | $1.43M | Buy |
29,041
+2,346
| +9% | +$109K | 0.1% | 182 |
|
|
2017
Q4 | $1.19M | Buy |
26,695
+1,165
| +5% | +$53.8K | 0.08% | 212 |
|
|
2017
Q3 | $1.29M | Buy |
25,530
+3,366
| +15% | +$171K | 0.09% | 192 |
|
|
2017
Q2 | $1.2M | Sell |
22,164
-9,802
| -31% | -$523K | 0.09% | 175 |
|
|
2017
Q1 | $1.71M | Buy |
31,966
+2,497
| +8% | +$127K | 0.13% | 141 |
|
|
2016
Q4 | $1.42M | Buy |
29,469
+17,930
| +155% | +$886K | 0.12% | 147 |
|
|
2016
Q3 | $619K | Buy |
11,539
+4,669
| +68% | +$256K | 0.06% | 212 |
|
|
2016
Q2 | $365K | Buy |
+6,870
| New | +$362K | 0.04% | 266 |
|
|
2015
Q2 | – | Sell |
-4,113
| Closed | -$243K | – | 340 |
|
|
2015
Q1 | $243K | Buy |
+4,113
| New | +$236K | 0.05% | 271 |
|
Other funds holding GSK
JEST
Voya Financial Advisors's GSK Position: Q1 2026 in Review
Voya Financial Advisors reduced its GSK (GSK) stake by 1.6% in Q1 2026, selling an estimated $29.9K and leaving 33,702 shares worth $1.81M. The position accounts for 0.18% of the portfolio, ranked #53.
Voya Financial Advisors first reported a position in GSK in Q1 2015 and has held it in 32 quarters since. The position peaked at $2.19M in Q4 2019. 1,032 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Voya Financial Advisors held 33,702 shares of GSK worth $1.81M as of Q1 2026.
- Voya Financial Advisors sold 552 GSK shares in Q1 2026, an estimated $29.9K.
- GSK made up 0.18% of Voya Financial Advisors's portfolio in Q1 2026, its #53 holding.
- Voya Financial Advisors first reported a position in GSK in Q1 2015 and has held it in 32 quarters since.
- Voya Financial Advisors's GSK position peaked at $2.19M in Q4 2019.
- 1,032 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Voya Financial Advisors's 13F filing for Q1 2026, filed 12 May 2026.